Abstract
In the 3rd year of the program 8 new molecular diagnostic services have been introduced to clinic in the management of breast-, lung-, colorectal cancers as well as in GIST and melanoma. Two patents have been filed for innovative modulation of mito/motogenic signaling pathways in cancer cells. In preclinical models of human cancer a functional imaging technique was developed to detect vascular eff ects of erythropoietin. Using a genomic approach, the sequential changes in human melanoma during systemic dissemination were determined revealing several novel potential prognostic factors and some interesting novel targets for therapy.
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Biomarkers, Tumor / genetics*
-
Bone Neoplasms / secondary
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / genetics
-
Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis
-
Colorectal Neoplasms, Hereditary Nonpolyposis / genetics
-
Female
-
Gastrointestinal Stromal Tumors / diagnosis
-
Gastrointestinal Stromal Tumors / genetics
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic
-
Genomics*
-
Humans
-
Hungary
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / genetics
-
Male
-
Melanoma / diagnosis
-
Melanoma / genetics
-
Neoplasms / blood supply
-
Neoplasms / diagnosis*
-
Neoplasms / genetics*
-
Neoplasms / pathology
-
Neovascularization, Pathologic / diagnosis*
-
Pathology, Molecular
-
Pharmacogenetics
-
Prognosis
-
Program Evaluation
-
Risk Factors
-
Signal Transduction / genetics
-
Skin Neoplasms / diagnosis
-
Skin Neoplasms / genetics
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor